Stay Informed with the Latest News
from GC Biopharma.
GC Biopharma Receives FDA Approval for its U.S. Plasma Collection Center in Calexico, California
-
Date
-
Views3372
YONGIN, SOUTH KOREA /
May 14, 2025 – GC
Biopharma, a South Korean pharmaceutical company, announced that its U.S.
subsidiary, ABO Holdings, has received FDA approval for its plasma collection center
located in Calexico, California.
Following the successful U.S. launch of ALYGLO (immune
globulin intravenous, human-stwk) 10% Liquid, GC Biopharma acquired ABO
Holdings in January to support the product's expected mid-to long-term revenue
growth.
With this approval, ABO Holdings is now operating all six
plasma collection centers—two each in California, Utah, and New Jersey. The
company plans to ramp up donor recruitment efforts in the second quarter, setting
the stage for substantial business growth in the second half of the year.
Additionally, ABO Holdings is on track to complete
construction of two new plasma centers in Texas and aims to obtain FDA approval
for both facilities by 2027. GC Biopharma anticipates gradual growth in its
source plasma business starting in the latter half of this year.
“With all six FDA-approved plasma centers now
operational, the company is well-positioned to achieve sustainable revenue
growth for Alyglo," said Eun-chul Huh, President and CEO of GC Biopharma. "This
milestone represents a significant contribution to our overall business
profitability."
About GC Biopharma
GC Biopharma (formerly known as Green Cross Corporation) is a
biopharmaceutical company headquartered in Yong-in, South Korea. The company
has over half a century of experience in the development and manufacturing of
plasma derivatives and vaccines, and is expanding its global presence with
successful US market entry of Alyglo™(intravenous immunoglobulin G) in 2024. In
line with its mission to meet the demands of future healthcare, GC Biopharma
continues to drive innovation by leveraging its core R&D capabilities in
engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery
platform to develop therapeutics for the field of rare disease as well as I&I
(Immunology & Inflammation). To learn more about the company, visit https://www.gcbiopharma.com/eng/